Cancer therapy-related complications in the bowel and mesentery: an imaging perspective

Ngo D, Jia JB, Green CS, Gulati AT, Lall C (2015) Cancer therapy related complications in the liver, pancreas, and biliary system: an imaging perspective. Insights Imaging 6(6):665–677 Jia JB, Lall C, Tirkes T, et al. (2015) Chemotherapy-related complications in the kidneys and collecting system: an imaging perspective. Insights Imaging 6(4):479–487 Mariani A, Camilleri M, Petersen IA, et al. (2008) Audit of suspected chronic intestinal pseudo-obstruction in patients with gynecologic cancer. Eur J Gynaecol Oncol 29:578 Hurwitz H, Fehrenbacher L, Novotny W, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342 Gressett SM, Shah SR (2009) Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 43:490–501 Van Cutsem E, Rivera F, Berry S, et al. (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20:1842–1847 Kelvin FM, Gramm HF, Gluck WL, et al. (1986) Radiologic manifestations of small-bowel toxicity due to floxuridine therapy. AJR Am J Roentgenol 146:39–43 Sharma RK (1988) Vincristine and gastrointestinal transit. Gastroenterology 95:1435 Holland JF, Scharlau C, Gailani S, et al. (1973) Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res 33:1258 Toghill PJ, Burke JD (1970) Death from paralytic ileus following vincristine therapy. Postgrad Med J 46:330–331 Hohneker JA (1994) A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 21:42 Dimopoulos MA, Eleutherakis-Papaiakovou V (2004) Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 117:508 Robinson BG, Paz-Ares L, Krebs A, et al. (2010) Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 95:2664 Cronin CG, O’Connor M, Lohan DG, et al. (2009) Imaging of the gastrointestinal complications of systemic chemotherapy. Clin Radiol 64:724 Santillan CS (2013) Computed tomography of small bowel obstruction. Radiol Clin N Am 51:17–27 Krishna SG, Zhao W, Grazziutti ML, et al. (2011) Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients: clinical and research implications. Cancer 117:648 Gorschluter M, Mey U, Strehl J, et al. (2005) Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol. 75:1–13 Sloas MM, Flynn PM, Kaste SC, Patrick CC (1993) Typhlitis in children with cancer: a 30-year experience. Clin Infect Dis. 17(3):484 Capria S, Vitolo D, Cartoni C, et al. (2004) Neutropenic enterocolitis in acute leukemia: diagnostic and therapeutic dilemma. Ann Hematol 83:195–197 Nesher L, Rolston KV (2013) Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy. Clin Infect Dis 56:711 Dhakshina MG, Salem U, Viswanathan C, Balachandran A, et al. (2013) Complications of oncologic therapy in the abdomen and pelvis: a review. Abdom Imaging 38:1–21 Kirkpatrick ID, Greenberg HM (2003) Gastrointestinal complications in the neutropenic patient: characterization and differentiation with abdominal CT. Radiology 226:668 Badgwell BD, Cormier JN, Wray CJ, et al. (2008) Challenges in surgical management of abdominal pain in the neutropenic cancer patient. Ann Surg 248:104–109 Ibrahim NK, Sahin AA, Dubrow RA, et al. (2000) Colitis associated with docetaxel-based chemotherapy in patients with metastasis breast cancer. Lancet 355:281–283 Tashiro M, Yoshikawa I, Kume K, Otsuki M (2003) Ischemic colitis associated with paclitaxel and carboplatin chemotherapy. Am J Gastroenterol 98:231–232 Li Z, Ibrahim NK, Wathen JK, et al. (2004) Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer 101:1508–1513 Kaur H, Loyer EM, David CL, et al. (2008) Radiologic findings in taxane induced colitis. Eur J Radiol 66:75–78 Feuerstadt P, Brandt LJ (2015) Update on colon ischemia: recent insights and advances. Curr Gastroenterol Rep 17(12):45 Schmitt M, Kuhn W, Harbeck N (1999) Thrombophylic state in breast cancer. Semin Thromb Hemost 25:157–166 Mosseri M, Fingert HJ, Varticovski L, et al. (1993) In vitro evidence that myocardial ischemia resulting from 5-FU chemotherapy is due to protein kinase C mediated vasoconstriction of vascular smooth muscle. Cancer Res. 53:3028–3033 Kuzel T, Esparaz B, Green D, et al. (1990) Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 65:885–889 Doll D, List A, Greco F, et al. (1986) Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 105:48–51 Allerton R (1996) Acute mesenteric ischemia associated with 5-FU, cisplatin, and vincristine chemotherapy. Clin Oncol 8:116–117 Hodi FS, O’Day SJ, McDermott DF, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711 Wolchok JD, Neyns B, Linette G, et al. (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:155 Topalian SL, Sznol M, McDermott DF, et al. (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020 Beck KE, Blansfield JA, Tran KQ, et al. (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte–associated antigen 4. J Clin Oncol 24:2283–2289 Heng Y, Schuffler MD, Haggitt RC, Rohrmann CA (1995) Pneumatosis intestinalis: a review. Am J Gastroenterol 90:1747–1758 Pear BL (1998) Pneumatosis intestinalis: a review. Radiology 207(1):13–19 Ho LM, Paulson EK, Thompson WM (2007) Pneumatosis intestinalis in the adult: benign to life-threatening causes. AJR Am J Roentgenol 188(6):1604–1613 Adar T, Paz K (2013) Images in clinical medicine: pneumatosis intestinalis. N Engl J Med 368(15):19 McGettigan MJ, Menias CO, Gao ZJ, Mellnick VM, Hara AK (2016) Imaging of drug-induced complications in the gastrointestinal system. Radiographics 36:71–87 Knechtle SJ, Davidoff AM, Rice RP (1990) Pneumatosis intestinalis. Surgical management and clinical outcome. Ann Surg 212:160 Wu SS, Yen HH (2011) Images in clinical medicine: pneumatosis cystoides intestinalis. N Engl J Med 365(8):16 Lee KS, Hwang S (2013) Hurtado Rúa SM, Janjigian YY, Gollub MJ. Distinguishing benign and life-threatening pneumatosis intestinalis in patients with cancer by CT imaging features. AJR Am J Roentgenol 200(5):1042–1047 Candelaria M, Bourlon-Cuellar R, Zubieta JL, Noel-Ettiene LM, Sanchez-Sanchez JM (2002) Gastrointestinal pneumatosis after docetaxel chemotherapy. J Clin Gastroenterol 34:444–445. Jamart J Cappell MS (2004) Colonic toxicity of administered drugs and chemicals. Am J Gastroenterol 99(6):1175–1190 Pneumatosis cystoides intestinalis (1979) A statistical study of 919 cases. Acta Hepatogastroenterol (Stuttg) 26:419 Meyers PA, Potter V, Wollner N, et al. (1985) Bowel perforation during initial treatment for childhood non-Hodgkin’s lymphoma. Cancer 56:259–261 Liaw CC, Huang JS, Wang HM, et al. (2006) Spontaneous gastroduodenal perforation in patients with cancer receiving chemotherapy and steroids. Cancer 72:1382–1385 Rose PG, Piver MS (1995) Intestinal perforation secondary to paclitaxel. Gynecol Oncol 57:270–272 Seewaldt VL, Cain JM, Goff BA, et al. (1997) A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer. Gynecol Oncol 67(2):137–140 Van Cutsem E, Tabernero J, Lakomy R, et al. (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499 Heimann DM, Schwartzentruber DJ (2004) Gastrointestinal perforations associated with interleukin-2 administration. J Immunother 27:254–258 Smith FO, Goff SL, Klapper JA, et al. (2007) Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. J Immunother. 30(1):130 Badgwell BD, Camp ER, Feig B, et al. (2008) Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 19:577–582 Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis [Review]. Lancet Oncol 10:559–568 Borofsky SE, Levine MS, Rubesin SE, et al. (2013) Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients. Abdom Imaging 38:265–272 Han ES, Monk BJ (2007) What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 105(1):3 Tanyi JL, McCann G, Hagemann AR, et al. (2011) Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecol Oncol. 120(3):464–469 Fuchs CS, Tomasek J, Yong CJ, et al. (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31 Qi WX, Sun YJ, Tang LN, et al. (2014) Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Crit Rev Oncol Hematol 89:394 Flinn IW, Kahl BS, Leonard JP, et al. (2014) Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 123:3406 Gopal AK, Kahl BS, de Vos S, et al. (2014) PI3 Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370:1008 Kawamoto S, Horton KM, Fishman EK (1999) Pseudomembranous colitis: spectrum of imaging findings with clinical and pathologic correlation. RadioGraphics 19(4):887–897 Thoeni RF, Cello JP (2006) CT imaging of colitis. Radiology 240(3):623–638 Emoto M, Kawarabayashi T, Hachisuga MD, Eguchi F, Shirakawa K (1996) Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Gynecologic Oncology 61(3):369–372 Husain A, Aptaker L, Spriggs DR, Barakat RR (1998) Gastrointestinal toxicity and clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. Gynecologic Oncology 71(1):104–107 Masciullo V, Mainenti S, Lorusso D, Margariti PA, Scambia G (2010) Lethal clostridium difficile colitis associated with paclitaxel and carboplatin chemotherapy in ovarian carcinoma: case report and review of the literature. Obstet Gynecol Int . doi:10.1155/2010/749789 National Cancer Institute Common Toxicity Criteria http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed 24 Jan 2016 Saliba F, Hagipantelli R, Misset JL, et al. (1998) Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 16:2745 Hecht JR (1998) Gastrointestinal toxicity or irinotecan. Oncology (Williston Park) 12:72 Grem JL, Shoemaker DD, Petrelli NJ, Douglass HO Jr (1987) Severe life-threatening toxicities observed in study using leucovorin with 5-fluorouracil. J Clin Oncol 5:1704 Petrelli N, Herrera L, Rustum Y, et al. (1987) A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559 Kuebler JP, Colangelo L, O’Connell MJ, et al. (2007) Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis. Cancer 110:1945 Bamat MK, Tremmel R, O’Neil JD, et al. (2010) Uridine triacetate: an orally administered, life-saving antidote for 5-FU overdose (abstract #9084). J Clin Oncol 28:656s Fuchs CS, Moore MR, Harker G, et al. (2003) Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21:807 de Bono JS, Oudard S, Ozguroglu M, et al. (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147 Pivot X, Koralewski P, Hidalgo JL, et al. (2008) A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 19:1547 Messersmith WA, Laheru DA, Senzer NN, et al. (2004) Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res 10:6522 Czito BG, Willett CG, Bendell JC, et al. (2006) Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol 24:656 Azim HA Jr, Agbor-Tarh D, Bradbury I, et al. (2013) Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. J Clin Oncol 31:4504 Akram S, Pardi DS, Schaffner JA, Smyrk TC (2007) Sclerosing mesenteritis: clinical features, treatment, and outcome in ninety-two patients. Clin Gastroenterol Hepatol 5:589 Kipfer RE, Moertel CG, Dahlin DC (1974) Mesenteric lipodystrophy. Ann Intern Med 80:582–588 Tedeschi CG, Botta GC (1962) Retractile mesenteritis. N Engl J Med 266:1035 Daskalogiannaki M, Voloudaki A, Prassopoulos P, et al. (2000) CT evaluation of mesenteric panniculitis: prevalence and associated diseases. AJR Am J Roentgenol 174:427 Horton KM, Lawler LP, Fishman EK (2003) CT findings in sclerosing mesenteritis (panniculitis): spectrum of disease. Radiographics 23:1561 Wat SY, Harish S, Winterbottom A, Choudhary AK, Freeman AH (2006) The CT appearances of sclerosing mesenteritis and associated diseases. Clin Radiol. 61(8):652–658 Valls C (2000) Fat-ring sign in sclerosing mesenteritis. AJR Am J Roentgenol 174:259–260 Ghanem N, Pache G, Bley T, et al. (2005) MR findings in a rare case of sclerosing mesenteritis of the mesocolon. J Magn Reson Imaging 21:632